Atlas FDA

MATRITECH NMP22 TEST KIT

FDA premarket approval P940035/S002 · decided 2000-01-18

Approval details

PMA number
P940035
Supplement
S002
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
MATRITECH NMP22 TEST KIT
Generic name
System, test, tumor marker, for detection of bladder cancer
Applicant
Abbott Diagnostics Scarborough, Inc.
Date received
1999-07-23
Decision date
2000-01-18
Days to decision
179 days
Decision code
APPR
Product code
NAH
Advisory committee
Immunology
Expedited review
No
Location
Scarborough, ME
Statement
The device is used as an aid 1)in the diagnosis of persons with symptoms or risk factors for transitional cell cancer (TCC) of the bladder (cut-off >= 7.5U/ml) in conjunction with and not in lieu of current standard diagnostic procedures and 2) in the management of patients with transitional cell carcinoma of the bladder, after surgical treatment to identify those patients with occult or rapidly recurring TCC (cut-off >10U/ml).

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
BinaxNOW COVID-19 Ag Card (K250273)Abbott Diagnostics Scarborough, Inc.2025-06-13
BinaxNOW™ COVID-19 Antigen Self Test (K243518)Abbott Diagnostics Scarborough, Inc.2025-02-11
ID NOW Influenza A & B 2 (K232775)Abbott Diagnostics Scarborough, Inc.2023-10-10
ID NOW COVID-19 2.0 (K221925)Abbott Diagnostics Scarborough, Inc.2023-08-10
ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2 (K220801)Abbott Diagnostics Scarborough, Inc.2022-06-24
ID NOW Influenza A & B 2 (K191534)Abbott Diagnostics Scarborough, Inc.2019-07-11